SABS Earnings & Financial Statements
SAB Biotherapeutics, Inc.
$2.88
-$0.05(-1.71%)
42
Overall
60
Value
45
Tech
21
Quality
Market Cap
$266.59M
Volume
679.31K
52W Range
$2.06 - $5.15
Target Price
$11.82
SABS earnings and financial statements: SAB Biotherapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SABS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $1.32M | $2.24M | $23.90M | $60.88M |
| Operating income | -$48.95M | -$42.91M | -$38.08M | -$28.92M | -$13.39M |
| EBITDA | $16.60M | -$29.33M | -$38.60M | -$15.12M | -$15.49M |
| Net income | $13.27M | -$34.11M | -$42.19M | -$18.74M | -$17.14M |
| EPS (diluted) | $-0.79 | $-3.68 | $-7.64 | $-4.30 | $-6.30 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $172.81M | $44.20M | $83.94M | $27.65M | $81.14M |
| Total liabilities | $21.32M | $18.23M | $26.64M | $19.85M | $42.59M |
| Shareholders’ equity | $151.49M | $25.97M | $57.30M | $31.06M | $38.55M |
| Cash and equivalents | $10.50M | $8.90M | $56.57M | $15.05M | $33.21M |
| Long-term debt | $5.00M | $3.86M | $4.05M | $4.53M | $5.42M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$44.78M | -$34.29M | -$25.12M | -$23.46M | $1.99M |
| Capital expenditure | -$932.7K | -$337.3K | -$197.2K | -$2.17M | -$10.94M |
| Free cash flow | -$45.71M | -$34.63M | -$25.32M | -$25.63M | -$8.96M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SABS | $2.88 | -1.7% | 679.31K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get SAB Biotherapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW